CND Life Sciences Celebrates 50,000 Syn-One Tests Milestone
Launched in 2019, the Syn-One Test is widely utilized by neurologists and healthcare providers across the nation. This innovative test significantly contributes to diagnosing various synucleinopathies, such as Parkinson's disease and dementia with Lewy bodies.
CND Life Sciences, a forefront player in medical technology, announced an impressive milestone: the completion of its 50,000th Syn-One Test. Designed to aid healthcare professionals in correctly diagnosing complex neurological conditions, this lab-developed test (LDT) is becoming increasingly essential in the medical field.
Richard Morello, CEO of CND, reflected on the achievement, noting, "We are deeply grateful for the dedication shown by our co-founders and team members to reach this remarkable milestone. Our commitment remains steadfast toward enhancing care for patients diagnosed with neurodegenerative diseases." This technology is helping thousands of families navigate the challenging landscape of these serious conditions.
The Importance of the Syn-One Test
The uniqueness of the Syn-One Test lies in its ability to apply proprietary techniques to detect phosphorylated alpha-synuclein in skin nerves. The examination involves collecting small skin samples from specific anatomical locations on each patient, which helps identify abnormal proteins that signify potential health issues.
In groundbreaking research funded by the National Institutes of Health (NIH), the Syn-One Test showcased remarkable sensitivity and specificity for diagnosed patients. This crucial study illustrates its clinical value in accurately identifying the onset of neurodegenerative disorders.
Enhanced Diagnostic Tools
Dr. Christopher Gibbons, a co-founder of CND, emphasized the need for accessible diagnostic tools. He stated, "The Syn-One Test fulfills a crucial requirement in the clinical community by providing reliable diagnostics for suspected synucleinopathies, drastically improving patient care." This approach empowers clinicians to make informed decisions, vital for managing their patients' health and treatment paths.
Statistics reveal a large population affected by these conditions, with 2.5 million individuals diagnosed in the U.S. alone. Each year, around 180,000 new cases emerge, highlighting the necessity for efficient diagnostic solutions like the Syn-One Test.
Clinical Impact on Patient Care
A recent study from a large medical center supported the importance of this testing, noting significant improvements in patient management for more than half of the cases analyzed. The research demonstrated tailored patient counseling and medication adjustments based on test results, leading to better overall care.
Andrea Merriam, the CEO of the Parkinson & Movement Disorder Alliance, pointed out, "The Syn-One Test plays a crucial role in helping individuals and families understand their health conditions, enabling informed decisions about future care options." Such advancements underscore CND's commitment to improving the quality of life for those facing neurodegeneration.
Continuous Innovation in Diagnosis
As neurological disorders remain challenging to diagnose, Dr. Kenneth M. Carnes highlighted the power of the Syn-One Test in making accurate assessments. He noted that this advancement is essential in developing effective treatment plans tailored for patients with synucleinopathy symptoms.
CND Life Sciences operates a CLIA-certified and CAP-accredited laboratory, dedicating its resources to enhancing diagnostic precision. The Syn-One Test's consistent performance in clinical trials exemplifies its reliability as a significant tool in neurologic assessments.
Future Directions of CND Life Sciences
Looking ahead, CND Life Sciences continues to engage in partnerships with biopharmaceutical organizations for innovative clinical trials. They are actively researching the early detection of neurodegenerative diseases and exploring synuclein quantification techniques.
About CND Life Sciences
CND Life Sciences is dedicated to supporting patients potentially diagnosed with neurodegenerative diseases. By providing cutting-edge diagnostic tests such as the Syn-One Test, CND enhances the ability of healthcare professionals to identify and manage these complex conditions.
The company aims to remain at the forefront of medical innovation, contributing to improving patient outcomes through collaboration and research advancements.
Frequently Asked Questions
What is the Syn-One Test?
The Syn-One Test is a laboratory-developed test designed to help diagnose synucleinopathies like Parkinson's disease using skin biopsies.
Why is the 50,000th test significant?
This milestone reflects the growing adoption of the Syn-One Test by healthcare professionals and its importance in diagnosing complex neurological conditions.
How does the Syn-One Test work?
The test analyzes small skin samples from specific locations to detect phosphorylated alpha-synuclein, which indicates potential neurological disorders.
Who can benefit from the Syn-One Test?
Patients suspected of having synucleinopathies and their clinicians can greatly benefit from the insights the Syn-One Test provides for diagnosis and management.
What future developments can we expect from CND Life Sciences?
CND Life Sciences is committed to enhancing diagnostic tools and conducting research for early detection and understanding of neurodegenerative diseases.
